By this point, the shape of the problem starts to change.

We are no longer asking whether beta cells can regenerate in principle. We have enough evidence to say that under the right experimental conditions, adult human beta cells can be coaxed back into proliferation. The better question now is more practical:

Because no single pathway explains regeneration on its own. And no single therapy, natural or pharmaceutical, appears to solve the entire problem. What the research points toward instead is a layered model: one set of interventions removes the brakes, another provides the growth signal, another protects the cells during the process, and another improves the terrain those cells are being asked to live in.

From Single Agents to Layered Logic

This is where both the clinical and holistic worlds have something useful to contribute.

Clinical research tends to focus on:

• defined pathways

• pharmacologic specificity

• measurable changes in proliferation or C-peptide

Holistic and terrain-based approaches tend to focus on:

• nutrient sufficiency

• inflammatory load

• gut-derived signaling

• metabolic rhythm

• long-term environmental compatibility

The tension between these worlds is often unnecessary.

One is often trying to flip the switch.The other is trying to make sure the wiring can handle it.

And when you look closely, the most promising strategies increasingly resemble combinations, not stand-alone interventions.

The First Layer: Releasing the Brake

The most direct pharmacologic regeneration work has centered on DYRK1A inhibition, especially with compounds like harmine. Harmine does not create beta cells from nothing. It removes one of the key molecular constraints keeping adult human beta cells locked in quiescence. This is the “permission” layer of regeneration.

But permission alone is not enough.

A cell can be told it is allowed to divide, yet still lack:

• enough survival signaling

• enough metabolic support

• enough identity stability

• or enough protection from stress

Which is why the regeneration story quickly becomes a story about synergy.

The Second Layer: Supplying the Growth Signal

One of the clearest examples of this comes from the synergy between DYRK1A inhibitors and GLP-1 receptor agonists.

Researchers at Mount Sinai and elsewhere showed that combining harmine-like DYRK1A inhibition with a GLP-1 receptor agonist produces a synergistic increase in human beta-cell proliferation, substantially beyond what either class achieves alone. More importantly, the combination increased functional human beta-cell mass in vivo, not just isolated proliferation markers in a dish. (Ackeifi 2020, Rosselot 2024, Tysoe 2024).

This is important for two reasons.

First, it confirms that beta cell growth is not controlled by a single pathway. Second, it shows that regeneration works best when:

• one intervention releases the brake

• another provides the trophic support

In simplified terms:

• Harmine / DYRK1A inhibition = “you may divide”

• GLP-1 agonism = “here is the support to survive, grow, and begin functioning again”

That is a very different model from simply “taking a regenerative compound.”

Why Incretins Matter Beyond Blood Sugar

GLP-1 agonists are often discussed as blood sugar drugs or appetite drugs, but in this context they need to be viewed more broadly.

GLP-1 receptor signaling supports:

• beta-cell survival

• cAMP generation

• insulin gene transcription

• anti-apoptotic signaling

• improved stress tolerance

This makes them especially relevant when paired with proliferation strategies. They do not merely increase insulin output; they help create a more supportive environment for a dividing beta cell.

This is also why there is growing interest in more metabolically expansive incretin strategies—such as retatrutide and other multi-receptor agonists—even though the strongest direct human regeneration data so far still center on GLP-1 agonists combined with DYRK1A inhibition.

The Clinical World: Focused Levers

From the clinical side, a layered regenerative strategy might include three broad classes of tools:

1. Proliferation-enabling therapies

• DYRK1A inhibitors such as harmine-derived compounds

• potentially adjunctive GSK-3β modulation (You can read about this pathway here)

2. Survival-supporting therapies

• GLP-1 receptor agonists

• verapamil for TXNIP reduction and calcium stabilization

3. Functional preservation therapies

• ER stress reducers

• oxidative stress reduction

• anti-inflammatory support

Verapamil is especially worth noting here. It is not a proliferative drug, but it appears to preserve beta-cell function by reducing intracellular calcium overload and lowering TXNIP, a stress-associated protein linked to beta-cell death. In newly diagnosed type 1 diabetes, verapamil has shown beta-cell preserving effects in both adult and pediatric trials, though not every later study has produced equally strong results. Still, it fits the survival-support layer well. (Forlenza 2023, Wych 2024)

This is a useful reminder that regenerative medicine is not only about making new cells. It is also about keeping stressed cells alive long enough to recover, mature and integrate.

The Holistic World: Building Compatibility

Now look at the same problem from the terrain side.

If proliferation is a conditional process, then nutrients, microbiome signaling, mineral balance, and inflammatory tone all become relevant—not as vague “wellness” tools, but as determinants of whether the regenerative signal can be received and sustained.

For example:

Berberine

Berberine is often discussed as a blood sugar support compound, but its relevance here is broader. It has been shown to increase endogenous GLP-1 signaling, likely through multiple mechanisms involving enteroendocrine stimulation, microbiome shifts, and short-chain fatty acid interactions. It is not equivalent to a GLP-1 agonist, but it does suggest a plausible terrain-based way of amplifying incretin tone. (Araj-Khodaei 2024, Sun 2018)

Fermentable fibers and SCFA support

Psyllium, inulin, flax meal, resistant starch, and similar fibers can increase the production of short-chain fatty acids, especially butyrate, which in turn support:

• endogenous GLP-1 release

• gut barrier integrity

• lower inflammatory signaling

• better microbiome ecology

This makes them part of the same regenerative conversation—not because fiber directly regenerates beta cells, but because it improves the signal quality and inflammatory environment in which regeneration has to occur. (Sun 2018)

Minerals and membrane stability

Magnesium, taurine, potassium, zinc, and phospholipid support may not “switch on” proliferation, but they influence:

• ATP handling

• calcium regulation

• insulin vesicle stability

• ER function

• membrane potential

In other words, they prepare the beta cell to behave like a beta cell again.

A More Useful Model of Synergy

At this point, it becomes easier to see regeneration as a sequence of cooperating layers:

Layer 1: Remove the brakes

• DYRK1A inhibition

• perhaps broader quiescence / repression relief

Layer 2: Provide growth and survival signaling

• GLP-1 receptor agonism

• cAMP / incretin support

• growth factor-compatible signaling

Layer 3: Protect the cell during the process

• verapamil

• antioxidant support

• ER stabilization

• calcium rhythm support

Layer 4: Improve the terrain

• microbiome stability

• endogenous incretin support

• nutrient sufficiency

• inflammatory tone reduction

• circadian alignment

Seen this way, “holistic” and “clinical” approaches are not opposing philosophies.

They are often addressing different layers of the same process.

Where the Two Worlds Usually Miss Each Other

This is why so many conversations around diabetes feel incomplete.

The clinical world often asks:

• Which molecular target can be manipulated?

• What increases human beta-cell mass?

• What preserves C-peptide?

The holistic world often asks:

• What is driving inflammation?

• Why is the gut-liver-pancreas axis distorted?

• What nutrients are missing?

Both are reasonable questions. But by themselves, both are partial.

A regenerative protocol built only on pharmaceuticals may stimulate growth in an unstable terrain. A protocol built only on supplements may improve terrain without ever strongly releasing the molecular brakes.

One improves the field. The other plants the seed.

A lasting result may require both.

A More Mature View of Action

So where does this fit into the bigger model?

Regeneration is not the first step. It is not even the central step.

It sits in the middle of a sequence:

1. Reduce the signals of danger

2. Restore compatibility and support

3. Release the barriers to growth

4. Support survival and maturation

5. Allow coordination to return

In that sense, the question is not:

“Should we choose clinical or holistic?”

It is:

“Which layer are we trying to influence, and what else has to be in place for it to work?”

That is a far more useful way to think.

Closing Thought

Beta-cell regeneration does not appear to be a single switch, a miracle compound, or a one-size-fits-all event.

It looks more like an orchestration.

One intervention may release the brake. Another may provide the trophic signal. Another may reduce stress. Another may restore the biochemical terrain.

And only when those layers begin to align does regeneration stop being theoretical and start becoming biologically plausible.

The future of regeneration may not belong to one therapy. It may belong to the right combination, in the right order, in the right terrain.

References — Section 6

• Ackeifi C, Wang P, Karakose E, et al.GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Sci Transl Med. 2020;12(530):eaaw9996.

• Rosselot C, Wang P, Acosta-Montalvo A, et al.Harmine and exendin-4 combination therapy safely increases human β cell mass in vivo. Sci Transl Med. 2024;16(754):eadg3456.

• Tysoe O.Combination therapy increases human β-cell mass in vivo. Nat Rev Endocrinol. 2024;20: 1–2.

• Araj-Khodaei M, Moghaddas A, Ghodsi R, et al.Berberine-induced glucagon-like peptide-1 and its anti-diabetic properties: a review. Phytother Res. 2024;38(1): 1–15.

• Sun Y, Xun K, Wang Y, Chen X.Restoration of GLP-1 secretion by berberine is associated with protection of colon enteroendocrine cells and increased intestinal SCFA production. Acta Pharm Sin B. 2018;8(4): 1–12.

• Yang WL, et al.Berberine metabolites stimulate GLP-1 secretion. Biochem Pharmacol. 2024; 1–12.

• Forlenza GP, et al.Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes. JAMA. 2023;329(12):990–999.

• Wych J, et al.Investigating the effect of verapamil on preservation of beta-cell function in type 1 diabetes (Ver-A-T1D). BMJ Open. 2024;14:e091597.